TCRR News and Press, TCR2 Therapeutics Inc. From 05/12/22

TCR2 Therapeutics press release (NASDAQ:TCRR): Q1 GAAP EPS of -$0.76 misses by $0.01. “We are very pleased with the momentum generated in the last quarter as we initiated the next phases on two clinical programs and expect to present in July an expanded dataset on 30 patients treated w...

- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial - IND Clearance for Phase 1/2 clinical trial of TC-510 - 30 patients treated with gavo-cel in the expanded Phase 1 trial; dataset review in July 2022 - Updates anticipated in the second half of 2022 CAMBR...

Gainers: TCR2 Therapeutics (TCRR) +16%. Precision BioSciences (DTIL) +16%. Alzamend Neuro (ALZN) +15%. BioSig Technologies (BSGM) +13%. Applied Therapeutics (APLT) +13%. Losers: ORIC Pharmaceuticals (ORIC) -29%. Applied Genetic Technologies (AGTC) -28%. NeuroSense Therapeutics (NRSN...

TCR2 Therapeutics press release (NASDAQ:TCRR): Q4 GAAP EPS of -$0.72 beats by $0.04. Cash, cash equivalents, and investments of $265.6M as of December 31, 2021 compared to $228.0 million as of December 31, 2020 For further details see: TCR2 Therapeutics GAAP EPS of -$0.72 beat...

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the fourth quarter ended De...

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced it will present a poster at the American Association of ...

CAMBRIDGE, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that on February 28, 2022 (the “Grant Date”...

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside cha...

CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Bus...

- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x10 8 cells/m 2 - Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022 - Initial data from TC-510 Phase 1/2 trial anticipated in 2H 2022 - Selection of lead allo...